Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $112.21 million versus the consensus estimate of $110.29 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• T. Rowe Price (TROW) PT Raised to $110 at TD Cowen
• Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'
• Albany International CFO takes medical leave, controller steps in